Efficacy and safety of bevacizumab for the treatment of glioblastoma (Review)

Experimental and Therapeutic Medicine

Volumn 11, Issue 2, 2016, Pages 371-380

  Yu, Zhiyun ^a   Zhao, Gang ^a   Zhang, Zhonghua ^a   Li, Yunqian ^a   Chen, Yong ^a   Wang, Nan ^a   Zhao, Zhongying ^b   Xie, Guifang ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b Department of Ophthalmology   (China)

Author keywords

Anti angiogenic; Bevacizumab; Glioblastoma; Vascular endothelial growth factor

Indexed keywords

ANTICONVULSIVE AGENT; BEVACIZUMAB; IRINOTECAN; TEMOZOLOMIDE; VASCULOTROPIN;

ANGIOGENESIS; BLEEDING; CRANIOTOMY; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FUNCTIONAL STATUS; GLIOBLASTOMA; HEADACHE; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; REVIEW; THROMBOEMBOLISM; TREATMENT RESPONSE;

EID: 84951098706     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2947     Document Type: Review

References (68)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
2. Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med 359: 492-507, 2008.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
5. Wen PY and DeAngelis LM: Chemotherapy for low-grade gliomas: Emerging consensus on its benefits. Neurology 68: 1762-1763, 2007.
6. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA and Yung WK: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17: 2572-2578, 1999.
7. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
8. Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027, 2005.
9. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
10. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
11. Siemann DW and Shi W: Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Semin Radiat Oncol 13: 53-61, 2003.
12. Miletic H, Niclou SP, Johansson M and Bjerkvig R: Anti-VEGF therapies for malignant glioma: Treatment effects and escape mechanisms. Expert Opin Ther Targets 13: 455-468, 2009.
13. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
14. Beal K, Abrey LE and Gutin PH: Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches. Radiat Oncol 6: 2, 2011.
15. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, et al: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370: 699-708, 2014.
16. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, et al: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370: 709-722, 2014.
17. Gil-Gil MJ, Mesia C, Rey M and Bruna J: Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol 7: 123-135, 2013.
18. Lu JF, Bruno R, Eppler S, Novotny W, Lum B and Gaudreault J: Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62: 779-786, 2008.
19. Specenier P: Bevacizumab in glioblastoma multiforme. Expert Rev Anticancer Ther 12: 9-18, 2012.
20. Wong ET, Gautam S, Malchow C, Lun M, Pan E and Brem S: Bevacizumab for recurrent glioblastoma multiforme: A meta-analysis. J Natl Compr Canc Netw 9: 403-407, 2011.
21. Stark-Vance V: Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol 7: 369, 2005.
22. Vredenburgh JJ, Desjardins A, Herndon JE II, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13: 1253-1259, 2007.
23. Vredenburgh JJ, Desjardins A, Herndon JE II, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25: 4722-4729, 2007.
24. Desjardins A, VJ, Reardon DA, Herndon JE, Marcello J, Peters K, Gururangan S, Sathornsumetee S, Rich JN and Friedman HS: Long-term survival from the initial trial of bevacizumab and irinotecan. J Clin Oncol 28 (15 Suppl): 191, 2010.
25. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740, 2009.
26. Cloughesy T, VJ, Day B, Das A and Friedman HS: The BRAIN Investigators:Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. J Clin Oncol 28 (15 Suppl): 181s, 2010.
27. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27: 740-745, 2009.
28. Cohen MH, Shen YL, Keegan P and Pazdur R: FDA drug approval summary: Bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14: 1131-1138, 2009.
29. Chamberlain MC and Johnston SK: Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol 96: 259-269, 2010.
30. Raizer JJ, Grimm S, Chamberlain MC, Nicholas MK, Chandler JP, Muro K, Dubner S, Rademaker AW, Renfrow J and Bredel M: A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116: 5297-5305, 2010.
31. Kreisl TN, Zhang W, Odia Y, Shih JH, Butman JA, Hammoud D, Iwamoto FM, Sul J and Fine HA: A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol 13: 1143-1150, 2011.
32. Nagane M, Nishikawa R, Narita Y, Kobayashi H, Takano S, Shinoura N, Aoki T, Sugiyama K, Kuratsu J, Muragaki Y, et al: Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol 42: 887-895, 2012.
33. Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D, Marosi C, Ochsenbein A, Pichler J, Roelcke U, et al: Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol 50: 630-635, 2011.
34. Zhang G, Huang S and Wang Z: A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme. J Clin Neurosci 19: 1636-1640, 2012.
35. Balañá C, Etxaniz O, Bugés C and Martínez A: Approval denied by the european medicines agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: A good idea or a grave error? Clin Transl Oncol 13: 209-210, 2011.
36. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, et al: Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29: 142-148, 2011.
37. Narayana A, Gruber D, Kunnakkat S, Golfinos JG, Parker E, Raza S, Zagzag D, Eagan P and Gruber ML: A clinical trial of bevacizumab, temozolomide and radiation for newly diagnosed glioblastoma. J Neurosurg 116: 341-345, 2012.
38. Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE II, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, et al: The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 17: 4119-4124, 2011.
39. Vredenburgh JJ, Desjardins A, Kirkpatrick JP, Reardon DA, Peters KB, Herndon JE II, Marcello J, Bailey L, Threatt S, Sampson J, et al: Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 82: 58-66, 2012.
40. Armstrong TS, Wen PY, Gilbert MR and Schiff D: Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol 14: 1203-1214, 2012.
41. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, et al: Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity and patterns of recurrence. Neurology 70: 779-787, 2008.
42. Gilbert MR, Wang M, Aldape K, Lassman A, Sorenson AG, Mikkelson T, Groves M, Wener-Wasik M, Regine W and Mehta M: RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). J Clin Oncol 27 (Suppl 15): 89s, 2009.
43. Gil MJ, de Las Peñas R, Reynés G, Balañá C, Peréz-Segura P, García-Velasco A, Mesia C, Gallego O, Fernández-Chacón C, Martínez-García M, et al: Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish neuro-oncology research group (GEINO). Anticancer Drugs 23: 659-665, 2012.
44. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L and Mikkelsen T: Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91: 329-336, 2009.
45. Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, Ciampa A, Kesari S and Wen PY: Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 11: 550-555, 2009.
46. Gurevich F and Perazella MA: Renal effects of anti-angiogenesis therapy: Update for the internist. Am J Med 122: 322-328, 2009.
47. Zhu X, Wu S, Dahut WL and Parikh CR: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am J Kidney Dis 49: 186-193, 2007.
48. Wu S, Kim C, Baer L and Zhu X: Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21: 1381-1389, 2010.
49. Rahmathulla G, Hovey EJ, Hashemi-Sadraei N and Ahluwalia MS: Bevacizumab in high-grade gliomas: A review of its uses, toxicity assessment, and future treatment challenges. Onco Targets Ther 6: 371-389, 2013.
50. Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, Kosteljanetz M and Lassen U: Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumors. Acta Oncol 48: 52-58, 2009.
51. Raval S, HS and Dorsett L: Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM). J Clin Oncol 25 (Suppl 18): 2078, 2007.
52. Bokstein F, Shpigel S and Blumenthal DT: Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112: 2267-2273, 2008.
53. Taillibert S, Hoang-Xuan K, Barrie M, Guiu S, Chauffert B, Cartalat-Carel S, Taillandier L, Fabbro M, Laigre M, Guillamo JS et al; ANOCEF group: Bevacizumab (B) with irinotecan (I) in recurrent glioblastoma (GBM): A national retrospective cohort of the ANOCEF (Association Des Neuro-Oncologues D'Expression Française) group. Neuro Oncol 12 (Suppl 4): iv52-iv53, 2010.
54. Keyrouz VF, Elias E, Chahine GY, Comair YG, Dimassi H and Kamar FG: Updated results of a phase II trial of bevacizumab and irinotecan in relapsed high-grade glioma. Neuro Oncol 12 (Suppl 3): iii47, 2010.
55. Pope WB, Lai A, Nghiemphu P, Mischel P and Cloughesy TF: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66: 1258-1260, 2006.
56. Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, et al: Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience. Neurology 72: 1217-1222, 2009.
57. Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE II, Bailey L, Peters KB, Friedman HS and Vredenburgh JJ: Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118: 1302-1312, 2012.
58. Verhoeff JJ, Lavini C, van Linde ME, Stalpers LJ, Majoie CB, Reijneveld JC, van Furth WR and Richel DJ: Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol 21: 1723-1727, 2010.
59. Soffietti R, Trevisan E, Ruda R, Bertero L, Bosa C, Fabrini MG and Lolli I: Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: Final results of a multicenter study of AINO (Italian Association of Neuro-oncology). J Clin Oncol 29: 2011.
60. Trevisan E, Ruda R, Picco E, Greco Crasto S, Caroli M, Fabrini A, Scotti V, Lolli I, Guarneri D and Soffietti R: Bevacizumab and fotemustine as salvage therapy in recurrent glioblastoma: A phase II multicenter Italian study. Neuro Oncol 12 (Suppl 3): iii49-iii50, 2010.
61. Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, Broholm H, Stockhausen MT and Poulsen HS: Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: A phase II trial. Neuro Oncol 12: 508-516, 2010.
62. Shapiro LQ, Beal K, Goenka A, Karimi S, Iwamoto FM, Yamada Y, Zhang Z, Lassman AB, Abrey LE and Gutin PH: Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma. Int J Radiat Oncol Biol Phys 85: 636-642, 2013.
63. Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, et al: Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 12: 1300-1310, 2010.
64. Niyazi M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, Geisler J, la Fougère C, Ertl L, Linn J, Siefert A and Belka C: Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys 82: 67-76, 2012.
65. Hundsberger T, Brügge D, Putora PM, Weder P, Weber J and Plasswilm L: Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neurooncology 112: 133-139, 2013.
66. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J and Abrey LE: Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75: 156-163, 2009.
67. Hainsworth JD, Shih KC, Shepard GC, Tillinghast GW, Brinker BT and Spigel DR: Phase II study of concurrent radiation therapy, temozolomide and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Clin Adv Hematol Oncol 10: 240-246, 2012.
68. Herrlinger U, Schafer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Stockhammer F, Ringel F, Braun C, et al: Bevacizumab, irinotecan and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT non-methylated glioblastoma patients: Updated results from the randomized multicenter GLARIUS trial. European J Cancer 49: S774, 2013.